CRISPR Takes on Diagnostics in the Wake of the...
Feb. 14, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Sherlock Biosciences
Main focus: Development of novel Cas-enzymes for diagnostics
Company stage: Commercial (diagnostics), pre-clinical (therapeutics)
Diseases: COVID-19 (diagnostics)
Genome editing tool: CRISPR-Cas12a, CRISPR-Cas12b, CRISPR-Cas13.
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://sherlock.bio/
Partners: Tolo Biotech
Sherlock Biosciences is a CRISPR diagnostics company. The company deploys its SHERLOCK™- and INSPECTR™-platforms that are based on novel Cas-enzymes, and so far, it has commercialised a novel CRISPR-based SARS-CoV-2 detection kit. The company is co-founded by Feng Zhang, who also co-founded Arbor Biotechnologies and Beam Therapeutics.
